Scilex Holding Company

Scilex Holding Company

SCLX·NASDAQ

$7.54

+1.8%
HealthcareDrug Manufacturers - General

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

At a Glance

Live Snapshot
Market Cap$64.02M
EPS-36.4800
P/E Ratio-0.21
Earnings Date06/03/2026
1.14%
Dividend Yield
3Y-
5Y-
10Y-
-1.21%
Dividend Payout Ratio
3Y-
5Y-
10Y-
Scilex Holding Company

Scilex Holding Company Dividend History

SCLX · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

SCLX Dividend Payment History

SCLX · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
sclx

Scilex Holding Company Payout Ratio Analysis

SCLX · NASDAQ
Dividends Paid
0.00
2025
Net Income
-358.73M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Excellent FCF coverage. Dividend is well-supported by actual cash generation with ample room for increases and business reinvestment.

Sustainability
Fair

Dividend sustainability questionable. Monitor closely for signs of stress. Consider whether yield justifies the risk.